Evidence map›Paper›PMID 26793421›Full record

ArticlePeerJ2016

Fibroblast growth factors as tissue repair and regeneration therapeutics.

Quentin M Nunes, Yong Li, Changye Sun, Tarja K Kinnunen, David G Fernig

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 112 citations in OpenAlex.

  1. Update on the Physiopathology of Keratoconus.Medical sciences (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Research progress on scar-free healing.Annals of medicine · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Implanted synthetic cells trigger tissue angiogenesis through de novo production of recombinant growth factors.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Quentin M Nunes *Department of Molecular and Clinical Cancer Medicine, NIHR Liverpool Pancreas Biomedical Research Unit, University of Liverpool, Liverpool, United Kingdom.
Yong Li *Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Changye Sun *Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Tarja K KinnunenDepartment of Biology, School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom.
David G FernigDepartment of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
University of Liverpool · GBUniversity of Huddersfield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell communication is central to the integration of cell function required for the development and homeostasis of multicellular animals. Proteins are an important currency of cell communication, acting locally (auto-, juxta-, or paracrine) or systemically (endocrine). The fibroblast growth factor (FGF) family contributes to the regulation of virtually all aspects of development and organogenesis, and after birth to tissue maintenance, as well as particular aspects of organism physiology. In the West, oncology has been the focus of translation of FGF research, whereas in China and to an extent Japan a major focus has been to use FGFs in repair and regeneration settings. These differences have their roots in research history and aims. The Chinese drive into biotechnology and the delivery of engineered clinical grade FGFs by a major Chinese research group were important enablers in this respect. The Chinese language clinical literature is not widely accessible. To put this into context, we provide the essential molecular and functional background to the FGF communication system covering FGF ligands, the heparan sulfate and Klotho co-receptors and FGF receptor (FGFR) tyrosine kinases. We then summarise a selection of clinical reports that demonstrate the efficacy of engineered recombinant FGF ligands in treating a wide range of conditions that require tissue repair/regeneration. Alongside, the functional reasons why application of exogenous FGF ligands does not lead to cancers are described. Together, this highlights that the FGF ligands represent a major opportunity for clinical translation that has been largely overlooked in the West.

Indexed as

Fibroblast growth factorFibroblast growth factor receptorHealingHeparan sulfateKlothoProtein therapeuticTissue repairUlcerWound

Identifiers

PMID26793421
PMCPMC4715458
OpenAlexW2203577167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.